Innoviva Inc (INVA)

HEALTH CARE: PHARMACEUTICALS
SIC: PHARMACEUTICAL PREPARATIONS

2000 SIERRA POINT PARKWAY BRISBANE, CA 94005

Develops small molecule medicines for unmet medical needs across a number of therapeutic areas including respiratory disease, bacterial infections, overactive bladder and gastrointestinal disorders. Of its six programs in development as of June 2005, two were in late stage development.

Data as of 2020-08-01
Market Cap1.372 Billion Shares Outstanding101.392 Million Avg 30-day Volume696.184 Thousand
P/E Ratio6.7 Dividend Yield EPS2.06
Price/Sales4.588 Price cash flow ratio5.6 Price free cash flow ratio6.4
Book Value4.51 Price to Tangible Book3.06 Alpha-0.0
Short Interest Ratio % Short Interest to Float R-squared0.137102
BETA1.02718 52-week High/Low15.62 / 7.58 Stddev0.119356

Are you looking for this stock instead?

View SEC Filings from INVA instead.
Q1 2020 All Institutions Hedge Funds 1
Filers who had this stock in their top 10: 1 2 (0.13%)
13F Filers holding this stock: 191 54 (3.54%)
Aggregate 13F shares on 03/31/2020: 73.847 Million 40.837 Million
Aggregate 13F shares on 12/31/2019: 74.885 Million 39.424 Million
Percent change: -1.39% 3.58%
Funds creating new positions: 34 9
Funds Adding to an existing position: 60 18
Funds closing out their position: 31 11
Funds reducing their position: 68 23
1 hedge funds as identified by whalewisdom.com through public filings.

View recent insider trading info

 
Innoviva Inc Chart by YCharts
Yahoo! Finance finviz
SEC Web Site SEC DEF 14A Filings

Check out our reporting and analysis

Funds Holding INVA (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
Click for Additional Filters
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Mutual Funds Holding INVA BETA

Active Schedule 13D and 13G filings

Please sign in first

Open Market Buys/Sells Last 60 Days

Open Market Buys (P)

none

Open Market Sells (S)

none

Exercise Derivative Conversion (M)

none

Current/Former Insiders

Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

GLAXOSMITHKLINE PLC

  • 10% Owner
 4,626,389 2020-07-24 0

DUNCAN BARBARA GAYLE

  • Director
 0 2020-07-01 0

BICKERSTAFF GEORGE

  • Director
 90,043 2020-07-01 1

DESPARBES ERIC CHIEF FINANCIAL OFFICER

  • Officer
 64,377 2020-06-18 0

MAMMEN MATHAI

  • Director
 0 2020-06-15 0

LEVINE ARNOLD J

  • Director
 0 2020-06-02 0

YOUNG WILLIAM D

  • Director
 0 2020-06-01 0

KEARNEY TERRENCE C

  • Director
 0 2020-06-01 0

TYREE JAMES L

  • Director
 13,069 2020-05-21 0

VAGELOS P ROY CHAIRMAN OF THE BOARD

  • Officer
  • Director
 538,711 2020-05-20 0

WINNINGHAM RICK E CHIEF EXECUTIVE OFFICER

  • Officer
  • Director
 1,395,628 2020-05-20 0

SHAFER BRADFORD J EVP, GEN. COUNSEL, SECRETARY

  • Officer
 261,527 2020-05-20 0

PASQUALONE FRANK SVP, CHIEF COMM OPS OFFICER

  • Officer
 410,108 2020-05-20 0

HULME GEOFFREY INTERIM PRINCIPAL EXEC OFFICER

  • Officer
 49,751 2020-05-20 4

ZHEN MARIANNE CHIEF ACCOUNTING OFFICER

  • Officer
 31,040 2020-05-20 5

RAIFELD PAVEL CHIEF EXECUTIVE OFFICER

  • Officer
 0 2020-05-20 1

LEPORE PATRICK G

  • Director
 400,000 2020-05-14 0

ABERCROMBIE GEORGE B

  • Director
 0 2020-05-12 0

WHITESIDES GEORGE M

  • Director
 55,064 2020-05-05 0

GUNDERSON ROBERT V JR

  • Director
 69,112 2020-04-28 0

MALKIEL BURTON G

  • Director
 86,777 2020-04-28 0

ODYSSEAS KOSTAS D

  • Director
 62,078 2020-04-24 1

DIPAOLO MARK

  • Director
 58,082 2020-04-24 1

SCHLESINGER SARAH J.

  • Director
 58,082 2020-04-24 1

HAIMOVITZ JULES

  • Director
 70,282 2020-04-24 1

FRIEDMAN CATHY

  • Director
 15,800 2020-02-20 0

BRINKLEY DAVID L

  • Director
 0 2019-07-18 0

RINGROSE PETER S

  • Director
 37,999 2019-04-30 0

WITEK THEODORE J. JR. SR. VP & CHIEF SCIENTIFIC OFF.

  • Officer
 247,767 2018-08-20 0

BLUM LEONARD M SEE REMARKS

  • Officer
 0 2018-05-14 0

FORE HENRIETTA

  • Director
 No longer subject to file 2017-12-31 0

AGUIAR MICHAEL W PRESIDENT & CHIEF EXEC OFFICER

  • Officer
  • Director
 980,907 2017-12-04 0

FAERM MICHAEL E. SR VP & CHIEF BUSINESS OFFICER

  • Officer
 279,422 2017-11-20 0

WALTRIP WILLIAM H

  • Director
 161,789 2017-04-20 0

PEPE PAUL

  • Director
 73,805 2017-04-20 0

LEE JUNNING SR. VP, TECHNICAL OPERATIONS

  • Officer
 234,071 2017-02-20 0

RADLY ADAM E CEO

191,600,227 2014-07-31 0

JONKER JEFFREY DAVID SENIOR VP, CORP. & BUS. DEV.

  • Officer
 0 2014-06-03 0

AUNGER PAUL SECRETARY

ADVISORS LLC

  • Officer
  • Director
  • 10% Owner
 28,097,122 2012-11-01 0

DRAZAN JEFFREY M

  • Director
 33,465 2012-05-01 0

INOVA TECHNOLOGY INC. PRESIDENT

  • Officer
  • Director
 35,700,884 2012-01-22 0

KITT MICHAEL SR. VICE PRESIDENT DEVELOPMENT

  • Officer
 32,738 2008-06-02 0

Insider Transactions Last 60 Days

Reporting Owners Transaction Date Transaction Code Shares Share Price Acquired or Disposed Shares Owned Following Transaction Combined shares owned after filing Direct/Indirect Ownership 10b-5
No current insider transactions
Transaction Code Definitions
Code Definition
A Grant, award or other acquisition pursuant to Rule 16b-3(d)
C Conversion of derivative security
D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
E Expiration of short derivative position
F Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3
G Bona fide gift
H Expiration (or cancellation) of long derivative position with value received
I Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities
J Other acquisition or disposition
L Small acquisition under Rule 16a-6
M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3
O Exercise of out-of-the-money derivative security
P Open market or private purchase of non-derivative or derivative security
S Open market or private sale of non-derivative or derivative security
U Disposition pursuant to a tender of shares in a change of control transaction
W Acquisition or disposition by will or the laws of descent and distribution
X Exercise of in-the-money or at-the-money derivative security
Z Deposit into or withdrawal from voting trust

Elevate your investments